Results of Annual General Meeting // Chi-Med
News Archive
Previous Article   |   Next Article
Regulatory Notice, RNS Announcements | 27 Apr 2016

Results of Annual General Meeting

London: Wednesday, April 27, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and the special resolution put to its Annual General Meeting (“AGM”) held on April 27, 2016 were duly passed.  The poll results of the resolutions were as follows:

 

 

 

Number of Votes (%)*

Resolutions

 

For

 

Against

 

Withheld#

 

 

 

 

 

 

 

1

To consider and adopt the statement of audited accounts and the reports of the directors and independent auditor for the year ended December 31, 2015.

 

50,155,497

 

280

 

21,058

 

(99.9994%)

 

(0.0006%)

 

 

 

 

 

 

 

 

 

 

2

(a) To re-elect Mr Simon To as a director.

 

49,077,310

 

62,950

 

1,036,575

 

(99.8719%)

 

(0.1281%)

 

 

 

 

 

 

 

 

 

 

 

(b) To re-elect Mr Christian Hogg as a director.

 

50,155,427

 

21,250

 

158

 

(99.9576%)

 

(0.0424%)

 

 

 

 

 

 

 

 

 

 

 

(c) To re-elect Mr Christian Salbaing as a director.

 

50,155,397

 

21,280

 

158

 

(99.9576%)

 

(0.0424%)

 

 

 

 

 

 

 

 

 

 

 

(d) To re-elect Ms Edith Shih as a director.

 

50,155,647

 

21,030

 

158

 

(99.9581%)

 

(0.0419%)

 

 

 

 

 

 

 

 

 

 

 

(e) To re-elect Mr Christopher Nash as a director.

 

49,116,261

 

1,060,416

 

158

 

(97.8866%)

 

(2.1134%)

 

 

 

 

 

 

 

 

 

 

 

(f) To re-elect Mr Michael Howell as a director.

 

49,055,784

 

1,120,892

 

159

 

(97.7661%)

 

(2.2339%)

 

 

 

 

 

 

 

 

 

 

 

(g) To re-elect Professor Christopher Huang as a director.

 

49,116,211

 

1,060,466

 

158

 

(97.8865%)

 

(2.1135%)

 

 

 

 

 

 

 

 

 

 

3

To re-appoint PricewaterhouseCoopers as the auditor of Chi-Med and authorise the board of directors to fix the auditor’s remuneration.

 

50,111,239

 

44,588

 

21,008

 

(99.9111%)

 

(0.0889%)

 

 

 

 

 

 

 

 

 

 

 

 

4

Ordinary Resolution No. 4(A)

:

To grant a general mandate to the directors of Chi-Med to issue additional shares.

 

50,174,133

 

2,371

 

331

 

(99.9953%)

 

(0.0047%)

 

 

 

 

 

 

 

 

 

 

 

 

 

Special Resolution No. 4(B)

:

To disapply pre-emption rights.

 

47,883,975

 

2,253,552

 

39,108

 

(95.5053%)

 

(4.4947%)

 

 

 

 

 

 

 

 

 

 

 

 

 

Ordinary Resolution No. 4(C)

:

To grant a general mandate to the directors of Chi-Med to repurchase shares of Chi-Med.

 

50,108,396

 

68,288

 

151

 

(99.8639%)

 

(0.1361%)

 

 


*  Percentages rounded to 4 decimal places
#  A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.

As at the date of the AGM, the number of issued shares of Chi-Med was 60,639,926, which was the total number of shares entitling the holders to attend and vote on the ordinary resolutions and special resolution proposed at the AGM.  

 

Ends

Contact

Investor Inquiries

 

Christian Hogg, CEO

+852 2121 8200

International Media Inquiries

 

Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk

U.S. Based Media Inquiries

 

Brad Miles, BMC Communications

+1 (917) 570 7340 (Mobile)
bmiles@bmccommunications.com

Susan Duffy, BMC Communications

+1 (917) 499 8887 (Mobile)
sduffy@bmccommunications.com

Investor Relations

 

Jillian Connell, The Trout Group

+1 (646) 378 2956
jconnell@troutgroup.com

David Dible, Citigate Dewe Rogerson

+44 20 7638 9571
+44 7967 566 919 (Mobile)
david.dible@citigatedr.co.uk

Panmure Gordon (UK) Limited

 

Richard Gray / Andrew Potts

+44 (20) 7886 2500

 

Notes to Editors

About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.